Comparing the current results to its competitors, Inflarx N V reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Inflarx N V's competitors' average revenue growth of 9.14 %, achieved in the same quarter.
Inflarx N V's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development of C5a and C5aR inhibitors and other therapeutic products targeting medical conditions addressed by its product candidates vilobelimab and izicopan. It faces challenges in retaining key personnel, recruiting qualified staff, and protecting intellectual property rights. The company also competes with other therapies and must manage regulatory approvals and designations, including orphan drug and breakthrough therapy status. Delays or failures in clinical trials, regulatory approvals, or intellectual property protection may impact its competitive position and commercialization efforts.
June 24, 2024
Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by severe inflammation in the lungs, leading to respiratory failure. It is a significant cause of mortality and morbidity worldwide, necessitating the urgent development of novel and effective therapies. In this article, we focus on the recent selection of Vilobelimab (GOHIBIC) by the Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2 clinical trial as a potential host-directed therapeutic for ARDS.Background:Vilobelimab, developed by InflaRx N.V., is a biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system. The complement system plays a critical...
May 21, 2024
Advancements in Combating Severe COVID-19: Potential Synergy of Vilobelimab in Combination with Other Immunomodulators:The ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated extensive research and development efforts to identify effective treatment options. Since the outbreak of COVID-19, multiple pharmaceutical companies have been at the forefront of developing therapeutics that can combat the severe manifestations of the disease. In this article, we explore the recent findings presented at the American Thoracic Society (ATS) 2024 International Conference by InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory therapeutics t...
January 4, 2024
Inflammation is a complex immune response that plays a crucial role in various diseases, including autoimmune disorders. Targeting the complement system, a key mediator of inflammation, has emerged as a promising therapeutic strategy. InflaRx N.V., a biotechnology company focused on developing anti-inflammatory therapeutics, recently announced positive topline results from the multiple ascending dose (MAD) phase of its Phase I trial for its novel C5aR inhibitor, INF904. These results reinforce the drug s potential as a best-in-class candidate for treating inflammatory conditions.The Complement System and C5aR Inhibition:The complement system, part of the body s innate immune response, is responsible for iden...
An2 Therapeutics Inc is a biotechnology company that develops therapeutics for the treatment of rare diseases. Their business model focuses on research and development of innovative drugs that target specific genetic mutations responsible for these rare conditions, aiming to provide effective and personalized treatments. By collaborating with pharmaceutical partners and leveraging their expertise in drug discovery, An2 Therapeutics Inc aims to bring their therapies to market and improve the lives of patients with rare diseases.
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Sources:
Inflarx N V’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inflarx N V versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
